Chickenpox (Varicella Zoster Infection)

October 2, 2017

Sinovac Biotech released preliminary top-line data from its phase III clinical trial assessing the Varicella vaccine against Chickenpox. The double-blinded, randomized, placebo-controlled trial was conducted in China. Approximately 6,000 healthy children from 1 to 12 years old completed the one dose vaccination schedule in August of 2016. Preliminary data showed that Sinovac’s Varicella vaccine was 87.1% (95% CI: 69.7%, 94.5%) efficacious against Chickenpox caused by VZV. In parallel, Sinovac conducted another clinical study that was comprised of 1,197 volunteers and designed to evaluate the consistency of three consecutive lots of Varicella vaccine manufactured by the company. The trial was conducted in children from 1 to 3 years old. The ratios of antibody GMTs on the 30 day of any two groups were calculated and the 95% confidence intervals of the ratios were all between 0.67 and 1.5, which indicates that the immunogenicity of the three vaccine lots is consistent. The company is on track for commercialization by the end of 2019.